Specifications for tirzepatide (pre-filtered pen):
Company: Hilma Biocare
Active ingredient half-life: approximately 5 days (117–120 hours)
Group: Peptide hormone
Subgroup: Injectable
Dosage: 10 mg
Application (Men): 2.5 to 15 mg
Packaging: 3 ml (Injectable Pen)
Contents (active ingredient): Tirzepatide
Water retention: not recognized
Flavoring: No
Product Description:
Tirzepatide is a dual agonist of GIP and GLP-1 receptors. Tirzepatide is an analogue of gastric inhibitory polypeptide (GIP), a human hormone that stimulates insulin release from the pancreas. Tirzepatide is a linear polypeptide of 39 amino acids, chemically modified by lipidation to improve its cellular uptake and metabolic stability.
Indication:
Treatment of type 2 diabetes mellitus and weight loss. Tirzepatide is used to improve glycemic control in combination with diet and exercise.
Mechanism of action
: Tirzepatide has a higher affinity for GIP receptors than for GLP-1 receptors, and this dual agonist action provides a more pronounced reduction in hyperglycemia compared to a selective GLP-1 receptor agonist. Tirzepatide mimics the action of natural GIP at the GIP receptor. At the GLP-1 receptor, tirzepatide preferentially forms cAMP (a messenger involved in the regulation of glycogen, sugar, and lipid metabolism) instead of attracting beta-arrestin. This combination of its preference for the GIP receptor and the specific signaling properties of GLP-1 increases insulin secretion. Tirzepatide increases adiponectin and adipokine levels, which are involved in the regulation of glucose and lipid metabolism, with a maximum increase of 26% from baseline after 26 weeks at a 10 mg dose.
Protection code:
How it works: Hilma Biocare™
prioritizes
consumer safety and regularly develops various protective measures for its products, ensuring patient safety and confidence in our products.
Specifications for tirzepatide (pre-filtered pen):
Company: Hilma Biocare
Active ingredient half-life: approximately 5 days (117–120 hours)
Group: Peptide hormone
Subgroup: Injectable
Dosage: 10 mg
Application (Men): 2.5 to 15 mg
Packaging: 3 ml (Injectable Pen)
Contents (active ingredient): Tirzepatide
Water retention: not recognized
Flavoring: No
Product Description:
Tirzepatide is a dual agonist of GIP and GLP-1 receptors. Tirzepatide is an analogue of gastric inhibitory polypeptide (GIP), a human hormone that stimulates insulin release from the pancreas. Tirzepatide is a linear polypeptide of 39 amino acids, chemically modified by lipidation to improve its cellular uptake and metabolic stability.
Indication:
Treatment of type 2 diabetes mellitus and weight loss. Tirzepatide is used to improve glycemic control in combination with diet and exercise.
Mechanism of action
: Tirzepatide has a higher affinity for GIP receptors than for GLP-1 receptors, and this dual agonist action provides a more pronounced reduction in hyperglycemia compared to a selective GLP-1 receptor agonist. Tirzepatide mimics the action of natural GIP at the GIP receptor. At the GLP-1 receptor, tirzepatide preferentially forms cAMP (a messenger involved in the regulation of glycogen, sugar, and lipid metabolism) instead of attracting beta-arrestin. This combination of its preference for the GIP receptor and the specific signaling properties of GLP-1 increases insulin secretion. Tirzepatide increases adiponectin and adipokine levels, which are involved in the regulation of glucose and lipid metabolism, with a maximum increase of 26% from baseline after 26 weeks at a 10 mg dose.
Protection code:
How it works: Hilma Biocare™
prioritizes
consumer safety and regularly develops various protective measures for its products, ensuring patient safety and confidence in our products.